[Evaluation of radiation therapy combined with intra-arterial infusion chemotherapy in patients with non-resectable pancreatic cancer]. 1992

H Ohigashi, and O Ishikawa, and S Nakamori, and S Masutani, and Y Sasaki, and M Kameyama, and M Hiratsuka, and T Kabuto, and H Furukawa, and S Imaoka
Dept. of Surgery, Center for Adult Diseases, Osaka.

This is a retrospective study to evaluate arterial infusion chemotherapy and radiotherapy for non-resectable pancreatic cancer without liver metastasis. Intra-arterial chemotherapy of the pancreas was performed for 17 patients, and 5 additionally received irradiation therapy. Five patients received radiation therapy alone. Both pain relief and tumor-reduction were more successful compared to the systemic chemotherapy group. In the locoregional treatment group, the patient survival rate was 50% at 1 year and 16% at 2 years. These rates were significantly higher than in the systemic chemotherapy group (p less than 0.01). Among the locoregional treatment groups, the median survival period was 7 months in radiation alone, 12 months in intra-arterial chemotherapy group, and 11 months in intra-arterial chemotherapy plus radiation group. These results suggested that locoregional treatment for pancreatic tumor is effective in increasing survival period and improving the quality of life.

UI MeSH Term Description Entries
D007261 Infusions, Intra-Arterial Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease. Infusions, Regional Arterial,Infusions, Intra Arterial,Infusions, Intraarterial,Arterial Infusion, Intra,Arterial Infusion, Regional,Arterial Infusions, Intra,Arterial Infusions, Regional,Infusion, Intra Arterial,Infusion, Intra-Arterial,Infusion, Intraarterial,Infusion, Regional Arterial,Intra Arterial Infusion,Intra Arterial Infusions,Intra-Arterial Infusion,Intra-Arterial Infusions,Intraarterial Infusion,Intraarterial Infusions,Regional Arterial Infusion,Regional Arterial Infusions
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D011882 Radiotherapy, High-Energy Radiotherapy using high-energy (megavolt or higher) ionizing radiation. Types of radiation include gamma rays, produced by a radioisotope within a teletherapy unit; x-rays, electrons, protons, alpha particles (helium ions) and heavy charged ions, produced by particle acceleration; and neutrons and pi-mesons (pions), produced as secondary particles following bombardment of a target with a primary particle. Megavolt Radiotherapy,High-Energy Radiotherapy,Radiotherapy, Megavolt,High Energy Radiotherapy,Radiotherapy, High Energy
D002408 Catheters, Indwelling Catheters designed to be left within an organ or passage for an extended period of time. Implantable Catheters,In-Dwelling Catheters,Catheter, In-Dwelling,Catheter, Indwelling,Catheters, In-Dwelling,In Dwelling Catheters,In-Dwelling Catheter,Indwelling Catheter,Indwelling Catheters
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine

Related Publications

H Ohigashi, and O Ishikawa, and S Nakamori, and S Masutani, and Y Sasaki, and M Kameyama, and M Hiratsuka, and T Kabuto, and H Furukawa, and S Imaoka
February 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
H Ohigashi, and O Ishikawa, and S Nakamori, and S Masutani, and Y Sasaki, and M Kameyama, and M Hiratsuka, and T Kabuto, and H Furukawa, and S Imaoka
August 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
H Ohigashi, and O Ishikawa, and S Nakamori, and S Masutani, and Y Sasaki, and M Kameyama, and M Hiratsuka, and T Kabuto, and H Furukawa, and S Imaoka
February 2009, Chinese medical journal,
H Ohigashi, and O Ishikawa, and S Nakamori, and S Masutani, and Y Sasaki, and M Kameyama, and M Hiratsuka, and T Kabuto, and H Furukawa, and S Imaoka
January 2000, Oncology reports,
H Ohigashi, and O Ishikawa, and S Nakamori, and S Masutani, and Y Sasaki, and M Kameyama, and M Hiratsuka, and T Kabuto, and H Furukawa, and S Imaoka
April 2003, International journal of clinical oncology,
H Ohigashi, and O Ishikawa, and S Nakamori, and S Masutani, and Y Sasaki, and M Kameyama, and M Hiratsuka, and T Kabuto, and H Furukawa, and S Imaoka
February 2023, BMC gastroenterology,
H Ohigashi, and O Ishikawa, and S Nakamori, and S Masutani, and Y Sasaki, and M Kameyama, and M Hiratsuka, and T Kabuto, and H Furukawa, and S Imaoka
November 2023, Medicine,
H Ohigashi, and O Ishikawa, and S Nakamori, and S Masutani, and Y Sasaki, and M Kameyama, and M Hiratsuka, and T Kabuto, and H Furukawa, and S Imaoka
July 2011, Oncology (Williston Park, N.Y.),
H Ohigashi, and O Ishikawa, and S Nakamori, and S Masutani, and Y Sasaki, and M Kameyama, and M Hiratsuka, and T Kabuto, and H Furukawa, and S Imaoka
June 2013, Journal of gastrointestinal oncology,
H Ohigashi, and O Ishikawa, and S Nakamori, and S Masutani, and Y Sasaki, and M Kameyama, and M Hiratsuka, and T Kabuto, and H Furukawa, and S Imaoka
January 2022, Cancers,
Copied contents to your clipboard!